Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
← catalyst calendarNCT07219927 · readout in 347 d
Sponsored by Supernus Pharmaceuticals, Inc. (industry) · SUPN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
120estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-31 | actual | When the study began enrolling |
| Primary completion | 2027-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson Disease
Intervention
- Other: Observational study
Primary outcomes
what the primary-completion date above is the date OFTitration Duration and Time to Optimized Dose
measured Approximately 52-60 weeks
Concomitant Parkinson's Disease (PD) Medication Adjustments
measured Approximately 52-60 week
The number of titration visits or dose adjustments required to reach the final optimized dose. This is a count of a specific event
measured Approximately 52-60 weeks
Permalink · SUPN's whole pipeline · Catalyst calendar · Every registered study · What changed